# US 2008/0306041 A1 · Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306041 A1
- Document ID: US20080306041A1
- Status: Published application
- Kind: A1
- Application number: 11/795,769
- Filed: 2006-01-23
- Published: 2008-12-11
- Earliest claimed: 2005-01-21
- Inventors: David S. Garvey
- Web page: https://patentgrep.com/patent/US20080306041A1

## CPC

- C07D 285/10: 1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/18: of the parathyroid hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 217/30: having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C 233/30: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
- C07C 233/65: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 255/54: containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C07C 275/34: having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/16: Tryptamines
- C07D 209/52: condensed with a ring other than six-membered
- C07D 209/88: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 223/16: Benzazepines; Hydrogenated benzazepines
- C07D 233/38: with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
- C07D 271/08: 1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
- C07D 273/00: Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D 281/06: not condensed with other rings
- C07D 311/18: substituted otherwise than in position 3 or 7
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 495/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension and (n) treating ophthalmic disorders. The cardiovascular compounds are preferably β-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, and antithrombotic and vasodilator compounds. The heterocyclic nitric oxide donor groups are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

## Claims

### Claim 1

A compound of Formula (I), (II), (III), (IV) or (V), or a pharmaceutically acceptable salt thereof:
wherein the compound of Formula (I) is:
wherein:
X3 is:
(1) —CH(CH3)2;
(2) —C(CH3)3;
Y3 is —C(O)—C6H5 or D1;
Z3 is:
R10 is:
(1) —C(O)—(CH2)k—CH3;
(2) —O—CH2—CH═CH2;
(3) a hydrogen;
(4) methyl;
(5) methoxy;
(6) cyclopentyl;
(7) halo;
(8) —O—CH2—C(O)—ND1-CH3;
(9) cyano;
(10) —CH2—CH═CH2; or
R11 is a hydrogen, methyl or a halo; or
R10 and R11 taken together are W4—U4—V4;
wherein W4—U4—V4 is
(1) —CH═C(R14)—ND1-;
(2) —CH═CH—CH2—;
(3) —CH2—CH═CH—;
(4) —CH═CH—CH═CH—;
(5) —O—CH2—CH(ONO2)—CH2—;
(6) —O—C(O)—CH═CH—;
(7) —(CH2)2—C(O)—ND1-;
(8) —(CH2)3—C(O)—;
(9) —CH2—CH(OD1)—CH(OD1)—CH2—;
(10) —S—(CH2)3—;
R12 is:
(1) —ND1-C(O)—(CH2)k—CH3;
(2) —(CH2)k—C(O)—OD1;
(3) —C(O)—(CH2)k—CH3;
(4) halo;
(5) —ND1-C(O)—N(C2H5)2;
(6) —CH2—C(O)—N(H)D1;
(7) —O—C(O)—CH3;
(10) —CH2—O—(CH2)2—O—CH(CH3)2;
(11) methyl; or
(12) —(CH2)2—O—CH3;
R13 is a hydrogen, methyl or halo;
R14 is a hydrogen or a lower alkyl;
R15 at each occurrence is independently selected from —OCH3, —OD1, —NO2, methyl or ND1-S(O)2—CH3;
k is an integer from 0 to 4;
D1 is a hydrogen, K or K′;
K is —(W3)a-Eb-(C(Re)(Rf))p1-Ec-(C(Re)(Rf))x—(W3)d—(C(Re)(Rf))y—(W3)i-Ej-(W3)g—(C(Re)(Rf))z—V3;
K′ is —(W3)a-Eb-(C(Re)(Rf))p1-Ec-(C(Re)(Rf))x—(W3)d—(C(Re)(Rf))y—(W3)i-Ej-(W3)g—(C(Re)(Rf))z—Re;
V3 is:
R24 is —C6H4R29, —CN, —S(O)2—C6H4R29, —C(O)—N(Ra)(Ri), —NO2, —C(O)—OR25 or —S(O)2—R25;
R25 is an aryl group, a lower alkyl group, a haloalkyl group, a hydroxyalkyl group or an arylalkyl group;
R26 is —C(O)— or —S(O)2—;
R29 is a hydrogen, —CN, —S(O)2—R25, —C(O)—N(Ra)(Ri), —NO2 or —C(O)—OR25;
T′ is oxygen, sulfur or NR6;
R6 is a hydrogen, a lower alkyl group, an aryl group;
a, b, c, d, g, i and j are each independently an integer from 0 to 3;
pi, x, y and z are each independently an integer from 0 to 10;
W at each occurrence is independently —C(O)—, —C(S)—, -T3-, —(C(Re)(Rf))h—, —N(Ra)Ri, an alkyl group, an aryl group, a heterocyclic ring, an arylheterocyclic ring, —(CH2CH2O)q1— or a heterocyclic nitric oxide donor;
E at each occurrence is independently -T3-, an alkyl group, an aryl group, —(C(Re)(Rf))h—, a heterocyclic ring, an arylheterocyclic ring, —(CH2CH2O)q1— or Y3;
Y3 is:
T is a —S(O)o—; a carbonyl or a covalent bond;
o is an integer from 0 to 2;
Rj and Rk are independently selected from an alkyl group, an aryl group, or Rj and Rk taken together with the nitrogen atom to which they are attached are a heterocylic ring;
T3 at each occurrence is independently a covalent bond, a carbonyl, an oxygen, —S(O)o— or —N(Ra)Ri;
h is an integer form 1 to 10;
q1 is an integer from 1 to 5;
Re and Rf are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, an alkylaryl, an alkylcycloalkyl, an alkylheterocyclic ring, a cycloalkylalkyl, a cycloalkylthio, an arylalklythio, an arylalklythioalkyl, an alkylthioalkyl, a cycloalkenyl, an heterocyclicalkyl, an alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano, an aminoalkyl, an aminoaryl, an aryl, an arylalkyl, an alkylaryl, a carboxamido, an alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, arylsulphonyloxy, a sulfonic ester, an alkyl ester, an aryl ester, a urea, a phosphoryl, a nitro, —U3—V5, V6, —(C(Ro)(Rp))k1—U3—V5, —(C(Ro)(Rp))k1—U3—V4, —(C(Ro)(Rp))k1—U3—C(O)—V6, or Re and Rf taken together with the carbons to which they are attached form a carbonyl, a methanthial, a heterocyclic ring, a cycloalkyl group, an aryl group, an oxime, an imine, a hydrazone, a bridged cycloalkyl group,
Ro and Rp are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, an alkylaryl, an alkylcycloalkyl, an alkylheterocyclic ring, a cycloalkylalkyl, a cycloalkylthio, an arylalklythio, an arylalklythioalkyl, an alkylthioalkyl a cycloalkenyl, an heterocyclicalkyl, an alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano an aminoalkyl, an aminoaryl, an aryl, an arylalkyl, an alkylaryl, a carboxamido, an alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a sulfonamido, an alkylsulfonamido, an arylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, arylsulphonyloxy, a sulfonic ester, an alkyl ester, an aryl ester, a urea, a phosphoryl, a nitro, —U3—V5, V6, or Ro and Rp taken together with the carbons to which they are attached form a carbonyl, a methanthial, a heterocyclic ring, a cycloalkyl group, an aryl group, an oxime, an imine, a hydrazone a bridged cycloalkyl group,
V4 is V3 or V6;
U3 is an oxygen, sulfur or —N(Ra)Ri;
V5 is —NO or —NO2 (i.e. an oxidized nitrogen);
V6 is:
Z5 is —CH2 or oxygen;
Z6 is —CH or nitrogen;
k1 is an integer from 1 to 3;
k1 is an integer from 1 to 3;
Ra is a lone pair of electrons, a hydrogen or an alkyl group;
Ri is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, in alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylaryl, an alkylsulfinyl, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfinyl, an arylsulfonyl, an arylsulphonyloxy, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, —CH2—C—(U3—V5)(Re)(Rf), a bond to an adjacent atom creating a double bond to that atom or —(N2O2—).M1+, wherein M1+ is an organic or inorganic cation; and
with the proviso that the compounds of Formula (I) must contain at least one heterocyclic nitric oxide donor group linked to the β-adrenergic antagonist through an oxygen atom, a nitrogen atom or a sulfur atom;
wherein the compound of Formula (II) is:
wherein:
Y4 is:
X4 is:
(1) methyl;
Z4 and Z4′ are independently selected from a methyl or a hydrogen;
R16 is:
(1) hydrogen;
(2) —C(O)—N(D1)H;
(3) —S(O)—CH3; or
(4) —S(O)2—N(D1)H;
R17 is a hydrogen, —OCH3 or —NO2;
o1 is an integer from 0 to 2;
R15, U3 and D1 are as defined herein; and
with the proviso that the compounds of Formula (II) must contain at least one heterocyclic nitric oxide donor group linked to the β-adrenergic antagonist through an oxygen atom, a nitrogen atom or a sulfur atom;
wherein the compound of Formula (III) is:
wherein:
X6 is:
(1) —U3D1;
(2) —O—CH2—CH3; or
Y6 is:
(1) —CH2—S—R21;
W6 is:
Z7 is:
(1) hydrogen;
(2) methyl; or
(3) —(CH2)4—N(H)D1;
R19 and R20 are a hydrogen; or
R19 and R20 taken together are an oxo; or
R20 and W6 taken together are:
R21 is:
(1) —C(O)—CH2—CH3;
(2) hydrogen;
(3) K;
(4) K′; or
R22 is —U3D1 or —OCH2—CH3;
D1, U3, K and K′ are as defined herein; and
with the proviso that the compounds of Formula (III) must contain at least one heterocyclic nitric oxide donor group linked to the angiotensin-converting enzyme (ACE) inhibitor through an oxygen atom, a nitrogen atom or a sulfur atom;
wherein the compound of Formula (IV) is:
wherein:
B6 is:
(2) a nitrogen;
G6 is:
D6 is:
or B6 and D6 taken together form a phenyl ring;
Q6 is a hydrogen; or
B6 is a nitrogen and O6 is CH9 and taken together form the ring:
U3 and D1 are as defined herein; and
with the proviso that the compounds of Formula (IV) must contain at least one heterocyclic nitric oxide donor group linked to the angiotensin-converting enzyme (ACE) inhibitor through an oxygen atom, a nitrogen atom or a sulfur atom;
wherein the compound of Formula (V) is:
wherein:
X7 is a hydrogen;
Y7 is
or X7 and Y7 taken together are:
R23 is a hydrogen or —OCH3;
R22, U3 and D1 are as defined herein; and
with the proviso that the compounds of Formula (V) must contain at least one heterocyclic nitric oxide donor group linked to the angiotensin-converting enzyme (ACE) inhibitor through an oxygen atom, a nitrogen atom or a sulfur atom.

### Claim 2 (depends on 1)

A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is a heterocyclic nitric oxide donor acebutolol, a heterocyclic nitric oxide donor alprenolol, a heterocyclic nitric oxide donor atenolol, a heterocyclic nitric oxide donor befunolol, a heterocyclic nitric oxide donor betaxolol, a heterocyclic nitric oxide donor bevantolol, a heterocyclic nitric oxide donor bisoprolol, a heterocyclic nitric oxide donor bopindolol, a heterocyclic nitric oxide donor bucindolol, a heterocyclic nitric oxide donor bucumolol, a heterocyclic nitric oxide donor bufetolol, a heterocyclic nitric oxide donor bunitrolol, a heterocyclic nitric oxide donor bupranolol, a heterocyclic nitric oxide donor butofilolol, a heterocyclic nitric oxide donor carazolol, a heterocyclic nitric oxide donor carteolol, a heterocyclic nitric oxide donor celiprolol, a heterocyclic nitric oxide donor cetamolol, a heterocyclic nitric oxide donor cloranolol, a heterocyclic nitric oxide donor epanolol, a heterocyclic nitric oxide donor esmolol, a heterocyclic nitric oxide donor indenolol, a heterocyclic nitric oxide donor levobunolol, a heterocyclic nitric oxide donor mepindolol, a heterocyclic nitric oxide donor metipranolol, a heterocyclic nitric oxide donor metoprolol, a heterocyclic nitric oxide donor moprolol, a heterocyclic nitric oxide donor nadolol, a heterocyclic nitric oxide donor nipradilol, a heterocyclic nitric oxide donor oxprenolol, a heterocyclic nitric oxide donor penbutolol, a heterocyclic nitric oxide donor pindolol, a heterocyclic nitric oxide donor practolol, a heterocyclic nitric oxide donor propranolol, a heterocyclic nitric oxide donor talinolol, a heterocyclic nitric oxide donor tertatolol, a heterocyclic nitric oxide donor tilisolol, a heterocyclic nitric oxide donor timolol, a heterocyclic nitric oxide donor toliprolol, a heterocyclic nitric oxide donor xibenolol; the compound of Formula (II) is a heterocyclic nitric oxide donor amosulalol, a heterocyclic nitric oxide donor arotinolol, a heterocyclic nitric oxide donor bufuralol, a heterocyclic nitric oxide donor carvedilol, a heterocyclic nitric oxide donor dilevalol, a heterocyclic nitric oxide donor labetalol, a heterocyclic nitric oxide donor landiolol, a heterocyclic nitric oxide donor nebivolol; a heterocyclic nitric oxide donor nifenalol, a heterocyclic nitric oxide donor pronethalol, a heterocyclic nitric oxide donor sotalol, a heterocyclic nitric oxide donor sulfinalol; the compound of Formula (III) is a heterocyclic nitric oxide donor alacepril, a heterocyclic nitric oxide donor captopril, a heterocyclic nitric oxide donor ceronapril, a heterocyclic nitric oxide donor enalapril, a heterocyclic nitric oxide donor enalaprilat, a heterocyclic nitric oxide donor fosinopril, a heterocyclic nitric oxide donor imidapril, a heterocyclic nitric oxide donor lisinopril, a heterocyclic nitric oxide donor moveltipril, a heterocyclic nitric oxide donor perindopril, a heterocyclic nitric oxide donor ramipril, a heterocyclic nitric oxide donor spirapril, a heterocyclic nitric oxide donor trandolapril; the compound of Formula (IV) is a heterocyclic nitric oxide donor benazepril, a heterocyclic nitric oxide donor cilazapril, a heterocyclic nitric oxide donor temocapril; the compound of Formula (V) is a heterocyclic nitric oxide donor delapril, a heterocyclic nitric oxide donor moexipril, a heterocyclic nitric oxide donor quinapril, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is a heterocyclic nitric oxide donor of Formula (VI), a heterocyclic nitric oxide donor bisoprolol of Formula (VII), a heterocyclic nitric oxide donor metoprolol of Formula (VIII), a heterocyclic nitric oxide donor propranolol of Formula (IX), a heterocyclic nitric oxide donor timolol of Formula (X); the β-adrenergic antagonist of Formula (II) is a heterocyclic nitric oxide donor carvedilol of Formula (XI), and the heterocyclic nitric oxide donor angiotensin-converting enzyme (ACE) inhibitor of Formula (III) is a heterocyclic nitric oxide donor captopril of Formula (XII), a heterocyclic nitric oxide donor enalapril of Formula (XIII), a heterocyclic nitric oxide donor fosinopril of Formula (XIV), a heterocyclic nitric oxide donor lisinopril of Formula (XV), a heterocyclic nitric oxide donor ramipril of Formula (XVI), a heterocyclic nitric oxide donor trandolapril of Formula (XVII), a heterocyclic nitric oxide donor trandolaprilat of Formula (XVII); the heterocyclic nitric oxide donor angiotensin-converting enzyme inhibitor of Formula (IV) is a heterocyclic nitric oxide donor benazepril of Formula (XIX); the heterocyclic nitric oxide donor angiotensin-converting enzyme inhibitor of Formula (V) is a heterocyclic nitric oxide donor moexipril of Formula (XX), a heterocyclic nitric oxide donor qunjiapril of Formula (XXI) or a pharmaceutically acceptable salt thereof,
wherein the compound of Formula (VI) is:
and the compound of Formula (VII) is:
and the compound of Formula (VII) is:
and the compound of Formula (IX) is:
and the compound of Formula (X) is:
and the compound of Formula (XI) is:
and the compound of Formula (XII) is:
and the compound of Formula (XIII) is:
and the compound of Formula (XIV) is:
and the compound of Formula (XV) is:
and the compound of Formula (XVI) is:
and the compound of Formula (XVII) is:
and the compound of Formula (XVIII) is:
and the compound of Formula (XIX) is:
and the compound of Formula (XX) is:
and the compound of Formula (XXI) is:
wherein
Rm—Rn taken together are a hydrogen atom; or
Rm is:
(i) —C—(O)—;
(ii) —C—(O)—NR6;
(iii) —C(O)—O—;
(iv) —C(O)—S;
(v) —CH2—O—;
(vi) —CH(CH3)—O—;
(vii) —N—C(O)—S—;
(viii) —N—C(O)—CH2—;
(ix) —N—C(O)—O—;
(x) a covalent bond;
(xi) —(C—(Re)(Rf))2-5—; or
(xii) —(C—(Re)(Rf))2-5-T′-C(O)—;
Rn is:
a hydrogen or:
wherein:
R6, R24, R25, R26, Rj, Rk, Re, Rf and T′ are as defined herein; and
with the proviso that the compounds of Formula (VI) to Formula (XXI) must contain at least one heterocyclic nitric oxide donor group.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the Formula (I) is:
wherein R27 and R28 are:
R27
R28
(1)
H
(2)
H
(3)
H
(4)
(5)
H
(6)
(7)
H
(8)
(9)
H
(10)
(11)
H
(12)
H
(13)
H
(14)
(15)
H
(16)
H
(17)
H
(18)
H
(19)
(20)
H
(21)
H
(22)
H
wherein:
R30 is a hydrogen or chlorine;
R33 is a hydrogen or a methyl group;
R35 is —(CH2)2—O—C(O)—CH3 or —(CH2)2—NH—C(O)—CH3; and
R36 is —CN, —C(O)—NH2 or —C(O)—OCH3.
wherein the compound of Formula (II) is:
and R27 and R28 are as defined herein;
wherein the compound of Formula (III) is:
wherein R31 and R32 are:
R31
R32
(1)
OH
(2)
(3)
OH
(4)
(5)
OH
(6)
(7)
(8)
OH
(9)
(10)
wherein
R34 is —S(O)2—C6H5; —CN, —C(O)—NH2 or —C(O)OCH3, and
R30 and R33 are as defined herein;
wherein the compound of Formula (IV) is:
wherein R31 and R32 are as defined herein;
wherein the compound of Formula (V) is:
wherein R31 and R32 are as defined herein.

### Claim 6 (depends on 2)

A method for treating a cardiovascular disease in a patient in need thereof comprising administering to the patient an effective amount of the composition of claim 2.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cardiovascular disease is congestive heart failure, acute decompensated heart failure, restenosis, hypertension, diastolic dysfunction, a coronary artery disease, myocardial infarction, cerebral infarction, atherosclerosis, atherogenesis, cerebrovascular disease, angina, aneurysm, ischemic heart disease, cerebral ischemia, myocardial ischemia, thrombosis, platelet aggregation, platelet adhesion, smooth muscle cell proliferation, a vascular or non-vascular complication associated with the use of a medical device, a wound associated with the use of a medical device, vascular or non-vascular wall damage, peripheral vascular disease, neointimal hyperplasia following percutaneous transluminal coronary angiograph, vascular grafting, coronary artery bypass surgery, a thromboembolic event, post-angioplasty restenosis, coronary plaque inflammation, hypercholesterolemia, embolism, stroke, shock, arrhythmia, atrial fibrillation or atrial flutter, or thrombotic occlusion and reclusion cerebrovascular incident.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cardiovascular disease is congestive heart failure, hypertension or diastolic dysfunction.

### Claim 9 (depends on 2)

A method for treating a renovascular disease in a patient in need thereof comprising administering to the patient an effective amount of the composition of claim 2.

### Claim 10 (depends on 9)

The method of claim 9, wherein the renovascular disease is renal failure or renal insufficiency.

### Claim 11 (depends on 2)

A method for treating diabetes; treating a disease resulting from oxidative stress; treating an endothelial dysfunction; treating a disease caused by endothelial dysfunction; treating cirrhosis; treating pre-eclampsia; treating osteoporosis; treating nephropathy; treating a peripheral vascular disease; treating portal hypertension or treating an ophthalmic disorder in a patient in need thereof comprising administering to the patient an effective amount of the composition of claim 2.

### Claim 12 (depends on 2)

The composition of claim 2, further comprising (i) at least one therapeutic agent; (ii) at least one nitric oxide enhancing compound; or (iii) at least one therapeutic agent and at least one nitric oxide enhancing compound.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the therapeutic agent is an aldosterone antagonist, an alpha adrenergic receptor agonists, an alpha-adrenergic receptor antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, an antidiabetic compound, an anti-hyperlipidemic compound, an antimicrobial compound, an antioxidant, an antithrombotic and vasodilator compound, a β-adrenergic antagonist, a calcium channel blocker, a carbonic anhydrase inhibitor, a digitalis, a diuretic, an endothelin antagonist, a hydralazine compound, a H2 receptor antagonist, a neutral endopeptidase inhibitor, a nonsteroidal antiinflammatory compound, a phosphodiesterase inhibitor, a potassium channel blocker, a platelet reducing agent, a prostaglandin, a proton pump inhibitor, a renin inhibitor, a selective cyclooxygenase-2 inhibitor, a steroid, or a combination of two or more thereof.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the therapeutic agent is at least one compound selected from the group consisting of an aldosterone antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, a β-adrenergic antagonist, a diuretic and a hydralazine compound.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the aldosterone antagonist is eplerenone or spironolactone; the angiotensin II antagonist is candesartan cilexetil, eprosartan mesylate, irbesartan, losartan potassium, medoxomil, telmisartan, trandolapril, trandolaprilat or valsartan; the angiotensin-converting enzyme inhibitor is benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril hydrochloride, quinapril hydrochloride, ramipril; the β-adrenergic antagonist is bisoprolol fumarate, carvedilol, metoprolol tartrate, propranolol hydrochloride or timolol maleate; the diuretic is amiloride hydrochloride, chlorthalidone, hydrochlorothiazide or triamterene; and the hydralazine compound is hydralazine hydrochloride.

### Claim 16 (depends on 12)

The composition of claim 12, wherein the nitric oxide enhancing compound is selected from the group consisting of a S-nitrosothiol, a nitrite, a nitrate, a S-nitrothiol, a sydnonimine, a NONOate, a N-nitrosoamine, a N-hydroxyl nitrosamine, a nitrosimine, a diazetine dioxide, an oxatriazole 5-imine, an oxime, a hydroxylamine, a N-hydroxyguanidine, a hydroxyurea, a furoxan or a nitroxide.

### Claim 17 (depends on 6, 9, 11)

The method of claims 6, 9 or 11, further comprising administering (i) at least one therapeutic agent; (ii) at least one nitric oxide enhancing compound (iii) at least one therapeutic agent and at least one nitric oxide enhancing compound.

### Claim 18 (depends on 17)

The method of claim 17, wherein the therapeutic agent is an aldosterone antagonist, an alpha adrenergic receptor agonists, an alpha-adrenergic receptor antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, an antidiabetic compound, an anti-hyperlipidemic compound, an antimicrobial compound, an antioxidant, an antithrombotic and vasodilator compound, a β-adrenergic antagonist, a calcium channel blocker, a carbonic anhydrase inhibitor, a digitalis, a diuretic, an endothelin antagonist, a hydralazine compound, a H2 receptor antagonist, a neutral endopeptidase inhibitor, a nonsteroidal antiinflammatory compound, a phosphodiesterase inhibitor, a potassium channel blocker, a platelet reducing agent, a prostaglandin, a proton pump inhibitor, a renin inhibitor, a selective cyclooxygenase-2 inhibitor, a steroid, or a combination of two or more thereof

### Claim 19 (depends on 17)

The method of claim 17, wherein the nitric oxide donor compound is selected from the group consisting of a S-nitrosothiol, a nitrite, a nitrate, a S-nitrothiol, a sydnonimine, a NONOate, a N-nitrosoamine, a N-hydroxyl nitrosamine, a nitrosimine, a diazetine dioxide, an oxatriazole 5-imine, an oxime, a hydroxylamine, a N-hydroxyguanidine, a hydroxyurea, a furoxan or a nitroxide.

### Claim 20 (depends on 1)

A kit comprising at least one compound of claim 1.

### Claim 21 (depends on 20)

The kit of claim 20, further comprising further comprising (i) at least one therapeutic agent; (ii) at least one nitric oxide enhancing compound; or (iii) at least one therapeutic agent and at least one nitric oxide enhancing compound.

### Claim 22 (depends on 21)

The kit of claim 21, wherein the (i) at least one therapeutic agent; (ii) at least one nitric oxide enhancing compound; or (iii) at least one therapeutic agent and at least one nitric oxide enhancing compound are in the form of separate components in the kit.
